Should You Buy Altimmune Stock in the UAE in 2025?

What is Altimmune?

How much is the Altimmune stock?

The price of Altimmune stock is rising this week. At $5.61 USD, the shares are up 2.19% over the last 24 hours and have gained 0.36% over the past week. Altimmune’s current market capitalization stands at $455.01 million, with a 3-month average daily volume of 2.54 million shares.

As the company is not profitable, its P/E Ratio is not applicable, and it does not offer a dividend yield. The stock’s beta of 1.11 points to higher-than-average volatility, which could interest AE investors seeking dynamic opportunities in biotechnology.

Our full analysis of the Altimmune stock

After a rigorous review of Altimmune’s most recent financial results, as well as its multi-year stock trajectory, our advanced analytical models—blending financial indicators, technical signals, real-time market data, and peer benchmarking—have offered a fresh perspective on this biotechnology innovator. With its strategic advances and promising product pipeline steadily gaining market attention, Altimmune stands at a critical juncture in the ever-competitive healthcare sector. So, why might Altimmune stock once again become a strategic entry point into the global biotech sector in 2025?

Recent Performance and Market Context

Altimmune (NASDAQ: ALT) has experienced a volatile yet telling price action over the past year, currently trading at $5.61 as of May 30, 2025, registering a daily uptick of 2.19%. While the 12-month decline of -25.30% and the six-month retreat of -34.54% indicate challenging macro and sector headwinds, recent stabilization—marked by a steady week (+0.36%)—signals that selling pressure may be abating.

Several notable positive events have contributed to renewed market focus:

• Clinical milestones: In May 2025, Altimmune initiated the pivotal Phase 2 RECLAIM trial, evaluating pemvidutide for alcohol use disorder, highlighting its continued pipeline expansion.
• Financial robustness: The company secured a $100 million credit facility with Hercules Capital, reinforcing its balance sheet and enhancing operational flexibility.
• Anticipated catalysts: The Q2 2025 release of IMPACT Phase 2b data for metabolic dysfunction-associated steatohepatitis (MASH) is expected to be a major catalyst, drawing attention from both institutional and retail investors.

On a broader scale, the biotechnology sector is benefiting from robust innovation, favorable global health policy trends, and a sustained appetite for next-generation therapeutics targeting obesity, metabolic, and liver diseases. For UAE-based investors seeking sector diversification and innovation-driven exposure, these factors help create a supportive long-term backdrop.

Technical Analysis

A deeper review of Altimmune’s technical picture reveals several constructive signals pointing toward emerging upside momentum:

• Relative Strength Index (RSI, 14 days): At 52.71, RSI is in neutral territory—neither overbought nor oversold—signaling potential headroom for further price appreciation.
• MACD (12,26,9): At 0.12, MACD has just flashed a bullish crossover, historically associated with upward trending phases.
• Key Moving Averages:
• The price sits above both the 20-day ($5.53) and 50-day ($5.20) moving averages, strengthening the short-to-medium-term bullish thesis.
• The 100-day ($5.82) and 200-day ($6.59) averages remain above the current price, indicating medium-term resistance but also substantial potential for a trend reversal.
• Support and Resistance Levels:
• Strong support at $5.57–$5.61 has held, with buyers emerging repeatedly at these levels.
• The first major resistance is seen at $5.78–$5.80; a breakout here could signal the beginning of a medium-term momentum shift.
• 52-Week Range: With a floor of $3.55 and a recent peak at $11.16, ALT’s technical landscape offers attractive risk/reward characteristics, especially for opportunistic investors able to capitalize on volatility.

In combination, these technical indicators suggest that Altimmune’s shares have transitioned into a stabilization phase, with credible evidence of a nascent bullish structure forming.

Fundamental Analysis

Altimmune’s fundamental story is anchored by the advancement of its differentiated pipeline and a notably strengthened financial base:

• Revenue and Profitability:
• Q1 2025 revenue came in at $20,000 (reflecting the company’s focus on pre-commercial clinical-stage development), with the loss per share materially improving to -$1.26 (TTM).
• Net loss narrowed to -$19.6M, demonstrating better cost management and operational discipline compared to the year prior.
• Balance Sheet Strength: A robust cash position of $149.83M, further enhanced by the new $100M credit facility, provides a substantial runway to fund ongoing and expanded clinical programs.
• Valuation: While the price-to-earnings ratio is not applicable for a pre-commercial biotech, the company’s current market capitalization of $455.01M stands in sharp contrast to consensus price targets averaging $21–$22, implying upside potential north of +270%.
• Strategic Moats and Innovation:
• The company’s flagship candidate, pemvidutide, is a dual GLP-1/glucagon receptor agonist with a unique profile emphasizing lean mass preservation in the high-growth obesity and MASH space.
• Active Phase 2/3 trials in multiple indications broaden addressable markets and reduce binary risk—a key competitive differentiator.
• The focused pipeline uniquely addresses large unmet needs, with the dual-agonist approach positioning Altimmune as an innovator among GLP-1 sector participants.

From a fundamental perspective, current valuations seem to underestimate the platform’s potential, especially as clinical and commercial milestones approach. For forward-looking investors, such a setup often provides a compelling long-term opportunity.

Volume and Liquidity

• Sustained Trading Volume: Altimmune boasts a 65-day average daily volume of 2.54 million, reflecting healthy liquidity and consistent market interest—two critical attributes for UAE institutional and active individual investors seeking efficient execution and fair price discovery.
• Market Capitalization and Float: At a sub-$500 million capitalization, ALT retains an attractive valuation float, capable of amplifying price moves in response to positive news or institutional inflows. This dynamic environment often rewards early, well-researched positioning.

Catalysts and Positive Outlook

The next six to twelve months are set to be particularly eventful for Altimmune, with a strong suite of potential value-creating catalysts:

• Clinical Trial Data:
• The impending Phase 2b IMPACT results for MASH (Q2 2025) could validate the differentiated efficacy of pemvidutide and unlock new partnership or licensing opportunities.
• Ongoing studies in obesity and alcohol use disorder further diversify the risk and expand the strategic narrative.
• Product Innovation: Pemvidutide’s dual-action mechanism continues to garner physician and payer interest. Favorable efficacy/safety data could leapfrog existing GLP-1 therapeutics.
• Growth Strategy: Expansion into additional metabolic and liver indications signals management’s commitment to leveraging core intellectual property, maximizing revenue opportunities across synergistic markets.
• ESG and Regulatory Trends: Increasing government and payer focus—particularly in the UAE—on metabolic and liver disease management (e.g., NAFLD/NASH) amplifies the relevance of Altimmune’s pipeline. Biotechs advancing truly transformative therapies in these domains are likely to benefit from favorable reimbursement and regulatory environments.
• Institutional Validation: Coverage by leading firms such as B. Riley Securities, Evercore ISI, and Goldman Sachs, as well as a consensus "Strong Buy" rating from 7–8 covering analysts, underscores growing institutional confidence.

In summary, Altimmune’s immediate pipeline milestones, paired with its unique technology and strong capital position, set the stage for significant potential upside.

Investment Strategies

Altimmune’s multi-dimensional setup allows for diverse, risk-adjusted investment strategies:

• Short-Term Positioning:
• Entry at current support ($5.57–$5.61) ahead of the Q2 2025 IMPACT phase 2b data could capture imminent price volatility in either a directional or event-driven trading strategy.
• Technical indicators (MACD positive, price above 20-/50-day moving averages) suggest near-term momentum could continue building.
• Medium-Term Approach:
• Momentum investors may favor exposure through the next two to four quarters, leveraging a pipeline rich in catalysts and persistent analyst optimism.
• Should resistance near $5.78–$5.80 break on high volume, upside toward the 100- and 200-day moving averages ($5.82 and $6.59, respectively) becomes technically attainable.
• Long-Term Exposure:
• With a robust balance sheet and multiple value inflection points over the next 12–24 months, long-term investors can target exposure now, seeking outsized returns as Altimmune advances toward late-stage development and potential commercial launches.
• Importantly, positioning today preempts potential re-rating scenarios should pivotal trial data and strategic announcements align favorably; the significant gap between current price and consensus price targets only enhances this asymmetric risk/reward.

In essence, whether viewed from a trading, thematic growth, or fundamental long-hold lens, the technical and fundamental backdrop appears to justify renewed portfolio attention.

Is It the Right Time to Buy Altimmune?

• The company is advancing a differentiated clinical-stage asset, pemvidutide, targeting the sizeable—and growing—metabolic and liver disease markets.
• Recent financial actions have fortified its balance sheet, reducing financing risk and supporting ongoing research and development.
• Trading activity remains robust, with technical indicators pointing toward a bullish reversal at established support, subsequently reinforced by a “Strong Buy” analyst consensus and a highly attractive risk/reward skew at current levels.
• Multiple catalysts are on the immediate horizon, most notably the imminent release of key Phase 2b data, which could trigger outsized market repricing and heightened investor engagement.
• In a region like the UAE, where investors are actively seeking diversification into tech-enabled healthcare innovation, Altimmune offers an uncommon blend of upside potential, strong liquidity, and near-term news flow.

Altimmune seems to represent an excellent opportunity for growth-oriented investors prepared for sector volatility, with profound fundamental strengths that justify serious consideration for new or increased positions in 2025. As the sector continues to pivot toward highly specialized therapeutics and as key pipeline events draw nearer, the stock may be entering a new bullish phase—potentially rewarding those who position ahead of the next wave of data-driven momentum.

With all elements aligned and a uniquely advantageous risk/reward profile, Altimmune offers investors an opportunity to participate in the front lines of biotech innovation, where conviction and patience may well be handsomely rewarded.

How to buy Altimmune stock in the UAE?

Buying Altimmune stock online is straightforward and secure when you use a regulated broker with a proven track record. Retail investors in the UAE can choose between two popular methods: buying shares outright (spot, or "cash" buying), or trading with Contracts for Difference (CFDs). Both options can be accessed on leading online trading platforms, each offering flexibility and control. In the following sections, you’ll find details on both approaches, plus a broker fee comparison lower down the page to help you make the best choice.

Cash buying

A cash purchase means you buy real Altimmune (ALT) shares listed on the NASDAQ, becoming the direct owner. This method suits those who prefer to invest for the long term and want to benefit from any future price appreciation or potential dividends (Altimmune does not currently pay dividends). UAE brokers typically charge a fixed commission for each order, usually ranging from AED 18 to AED 25 (about $5 to $7), regardless of the size.

Example

If the Altimmune share price is $5.61 (as of 30 May 2025), with a $1,000 investment and a $5 brokerage fee:
- Purchase amount: $1,000 - $5 = $995 available to invest
- Number of shares: $995 ÷ $5.61 ≈ 177 shares

✔️ Gain scenario

If the share price rises by 10%, your shares would be worth approx. $6.17 each. Your position is now valued at $1,092.
Result: +$100 gross gain, or +10% on your initial investment (excluding other fees and currency conversion, if any).

Trading via CFD

CFD trading allows you to speculate on Altimmune’s share price movements without owning the underlying stock. CFDs are leveraged products, commonly offering up to 5x leverage for US shares, meaning your potential gains (and losses) are multiplied. Instead of a fixed fee, you pay the spread (the difference between buy/sell prices), plus overnight financing fees if you hold the position open beyond one day.

Example

With a $1,000 deposit and 5x leverage, your market exposure becomes $5,000.
- If Altimmune stock rises by 8%, your CFD position would gain 8% × 5 = 40%.
Result: +$400 gain on your $1,000 stake (excluding spread and overnight fees).

Final advice

Before investing, always compare the fees, commissions, and trading conditions of different brokers, as these can impact your returns. Whether you choose cash buying or CFD trading will depend on your financial goals: long-term investors may prefer direct ownership, while active traders might be drawn to the flexibility and leverage that CFDs offer. For a comprehensive broker comparison tailored to UAE investors, check the table provided further down this page.

Our 7 tips for buying Altimmune stock

The latest news about Altimmune

Altimmune shares recorded a 2.19% intraday increase, outperforming the broader market over the past 24 hours. This short-term momentum is reinforced by a recent positive trend over the last week (+0.36%) and technical buy signals from both moving averages and MACD, highlighting increasing investor interest. The observed performance is particularly relevant for institutional investors in AE seeking tactical entry points into high-volatility, high-potential biotech stocks that are still relatively undervalued by traditional metrics, with the current share price ($5.61) significantly below the consensus analyst target of $21.

The company strengthened its financial position by closing a $100 million credit facility with Hercules Capital in May 2025. This facility enhances Altimmune’s available liquidity, underpinning the ongoing funding of vital late-stage clinical trials without diluting shareholder value through equity raises. For regional investors evaluating US small-cap biotech exposure, such robust access to capital is a constructive indicator of operational continuity and reduces near-term financial risk, which is especially pertinent in environments where regional or international investment flows may be sensitive to balance sheet resilience.

Major clinical progress was reported in Q1 2025, including the initiation of the RECLAIM Phase 2 study evaluating pemvidutide in alcohol use disorder. This development marks a strategic pipeline expansion beyond metabolic and hepatic applications, positioning Altimmune's lead asset, pemvidutide, as a differentiated dual-agonist GLP-1/glucagon therapy. The expansion into new indications not only diversifies revenue potential but also demonstrates Altimmune’s commitment to addressing unmet clinical needs—an approach that often aligns with healthcare innovation strategies prominent in the AE region’s sovereign and institutional investment bodies.

Upcoming catalyst: Data from the pivotal IMPACT Phase 2b MASH study are expected in Q2 2025, with strong anticipation from analysts. Positive readouts could serve as a transformational inflection point for the stock, amplifying market attention as analysts maintain a “Strong Buy” consensus and collectively project a 270%+ upside from current levels. For AE-based investors tracking global healthcare innovation, this event could provide significant visibility, especially as regional interests continue to explore partnerships and co-development in medtech and biotech fields.

Altimmune retains a healthy cash position ($149.83M at Q1 2025) and is recognized for its advanced clinical pipeline targeting obesity and metabolic diseases. Despite no physical presence or direct commercial footprint yet in the AE market, Altimmune’s differentiated science and strong analyst endorsement have the potential to attract capital from Middle Eastern institutional players seeking exposure to next-generation metabolic disorder treatments. As worldwide demand for obesity therapies grows—including in the GCC region—Altimmune remains well-positioned to benefit from expanded licensing, partnering, or direct market entry opportunities.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.